Heartflow Secures $300M to Revolutionize Coronary Care with AI-Driven Precision

Heartflow, the global leader in AI-driven coronary artery disease (CAD) management, is thrilled to announce that it has raised $300,000,000 in its latest funding round. This major capital infusion underscores the remarkable progress and unwavering confidence that investors have in Heartflow’s groundbreaking approach to transforming CAD care. With CAD remaining the world’s leading cause of death, Heartflow’s innovative platform—Heartflow One—has revolutionized the detection and management of the disease. By using advanced AI-driven methods to convert a single CT scan into a personalized, precision 3D heart model, clinicians are now empowered with unparalleled clarity and confidence in diagnosing and treating CAD. This state-of-the-art technology, fortified by Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, has garnered acceptance through the ACC/AHA Chest Pain Guideline and is supported by more than 600 peer-reviewed publications. The new funds will be strategically deployed to further enhance research and development, expand clinical studies, and solidify its global market presence. With over 400,000 patients treated and its solution adopted by more than 1,400 leading institutions, Heartflow continues to redefine the standard of coronary care worldwide. The company, headquartered in Mountain View, California, and operating across the United States, Europe, and Japan, envisions a future where CAD becomes a manageable condition rather than an insidious threat. The capital will also support further market penetration and the expansion of its innovative capabilities, ensuring that clinicians across the globe have access to comprehensive coronary care. By making CAD screenable, diagnosable, and manageable, Heartflow is setting a new benchmark in healthcare, ultimately empowering clinicians to extend and enhance patients’ lives.